Literature DB >> 31048286

Areas of agreement in the management of childhood non-infectious chronic anterior uveitis in the UK.

Ameenat Lola Solebo1,2,3,4, Jugnoo S Rahi5,2,3,4, Andrew D Dick2,6, Athimalaipet V Ramanan7, Jane Ashworth8, Clive Edelsten3.   

Abstract

BACKGROUND/AIMS: There is a paucity of high-level evidence to support the management of childhood uveitis, particularly for those children without juvenile idiopathic arthritis uveitis (JIA). We undertook a modified Delphi consensus exercise to identify agreement in the management of chronic anterior uveitis (CAU), the most common manifestation of childhood disease.
METHODS: A four-round, two-panel process was undertaken between June and December 2017. Paediatric uveitis specialists identified through multiple sources, including a multicentre network (the Paediatric Ocular Inflammation Group), were invited to participate. They were asked whether they agreed with items derived from existing guidelines on the management of JIA-U when extrapolated to the population of all children with CAU. Consensus was defined as agreement greater than or equal to 75% of respondents.
RESULTS: 26 of the 38 (68%) invited specialists participated with the exercise, and response rates were 100% for rounds one to three, and 92% for round four. Consensus was reached on 23 of the 44 items. Items for which consensus was not reached included management at presentation, use of systemic and periocular steroids for children with severe disease and the role of conventional steroid sparing immunosuppressants beyond methotrexate.
CONCLUSION: The areas of management uncertainty at the level of the group, as indicated by absence of consensus, reflect the areas where the evidence base is particularly poor. Our findings identify the key areas for the future research needed to ensure better outcomes for this blinding childhood ocular inflammatory disorders. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  child; delphi technique; disease management; uveitis

Mesh:

Substances:

Year:  2019        PMID: 31048286     DOI: 10.1136/bjophthalmol-2018-313789

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  6 in total

Review 1.  Research progress in drug therapy of juvenile idiopathic arthritis.

Authors:  Wen-Jia Zhao; Jiang-Hong Deng; Cai-Feng Li
Journal:  World J Pediatr       Date:  2022-04-01       Impact factor: 2.764

Review 2.  Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis.

Authors:  William D Renton; Jennifer Jung; Alan G Palestine
Journal:  Cochrane Database Syst Rev       Date:  2022-10-14

3.  Development of a Nationally Agreed Core Clinical Dataset for Childhood Onset Uveitis.

Authors:  Ameenat Lola Solebo; Salomey Kellett; Jugnoo Rahi; Reshma Pattani; Clive Edelsten; Andrew D Dick; Alastair Denniston
Journal:  Front Pediatr       Date:  2022-06-21       Impact factor: 3.569

Review 4.  Paediatric autoimmune and autoinflammatory conditions associated with uveitis.

Authors:  Najiha Rahman; Harry Petrushkin; Ameenat Lola Solebo
Journal:  Ther Adv Ophthalmol       Date:  2020-11-02

5.  Practice patterns regarding regional corticosteroid treatment in noninfectious Uveitis: a survey study.

Authors:  Matthew McHarg; LeAnne Young; Natasha Kesav; Mehmet Yakin; H Nida Sen; Shilpa Kodati
Journal:  J Ophthalmic Inflamm Infect       Date:  2022-01-04

6.  Risk Factors Leading to Anti-TNF Alpha Therapies in Pediatric Severe Uveitis.

Authors:  Delphine Osswald; Anne-Cécile Rameau; Joëlle Terzic; Christelle Sordet; Tristan Bourcier; Arnaud Sauer
Journal:  Front Pediatr       Date:  2022-03-04       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.